Capstone <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Cuts Convertible Note Conversion Price to $0.75
Capstone Therapeutics Corporation has announced an amendment to its previously disclosed debt transaction with an institutional investor. The company had issued senior secured convertible notes totaling up to approximately $10.9 million, with original principal amounts of $3.27 million and $3.54 million for notes issued in July and October 2025, respectively. Initially, the conversion prices for these notes were set at $1.72 (later reduced to $1.00) and $1.10 per share. On November 28, 2025, Capstone and the investor agreed to further reduce the conversion price to $0.75 for the remaining balance of the July 2025 note and for $1.77 million of the October 2025 note's principal. The company has registered a total of 8,388,336 shares of common stock for potential issuance upon conversion of these notes.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-116037), on November 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.